Table 1.
Baseline Patient Characteristics
| Characteristic | Total (N = 172) |
|---|---|
| Median age (range), yr (IQR) | 55 (51–60) |
| Male sex, no. (%) | 136 (79) |
| Race, no. (%) | |
| Black | 142 (82.5%) |
| White | 22 (13.4%) |
| Hispanic | 6 (3.5%) |
| Asian | 0 (0%) |
| Other | 1 (0.6%) |
| HCV acquisition risk factor, no. (%) | |
| Heterosexual | 74 (43%) |
| MSM | 55 (32%) |
| IDU | 35 (20%) |
| IDU and MSM | 8 (5%) |
| Median BMI (kg/m2; IQR) | 26 (23–29) |
| HCV genotype, no. (%) | |
| 1 | 163 (94.8%) |
| 1a | 85 (49.4%) |
| 1b | 34 (19.8%) |
| Unknown | 44 (25.6%) |
| 2 | 8 (4.7%) |
| 3 | 1 (0.6%) |
| Median HCV RNA (IQR), log10 IU/mL | 6.29 (5.87–6.66) |
| Cirrhosis, no. (%) | 28 (16%) |
| Fib-4 ≥3.25 | 35 (20%) |
| Median Scr, µmol/L (IQR) | 88.4 (79.6–106.1) |
| Median ALT, U/L (IQR) | 38 (27–58) |
| Median Platelets, ×103/µL (IQR) | 188 (151–229) |
| Treatment experienced, no. (%) | 36 (21%) |
| Nonresponder | 26 (72.2%) |
| Relapse | 4 (11.1%) |
| Partial responder | 3 (8.3%) |
| Unknown past response | 3 (8.3%) |
| Previous HCV treatments, no. (%) (n= 41) | |
| IFN/RBV or PEG-IFN/RBV | 35 (85.3%) |
| PEG-IFN alone | 1 (2.4%) |
| PEG-IFN/RBV + TPV or BOC | 4 (9.7%) |
| Treatment unknown | 1 (2.4%) |
| Characteristic | Total (N = 172) |
| HIV-1 RNA | |
| Undetectable, no. (%) | 158 (92%) |
| Detectable and <100 copies/mL, no. (%) | 8 (5%) |
| 100–399 copies/mL | 5 (3%) |
| >400 copies/mL | 1 (1%) |
| Median CD4+ count (IQR), cells/µL | 494 (315–706) |
| HIV-1 Treatment, no./total | |
| Protease inhibitor | 82 (48%) |
| Darunavir + ritonavir | 41 |
| Atazanavir + ritonavir | 30 |
| Lopinavir + ritonavir | 9 |
| Atazanavir | 2 |
| NNRTI | 53 (31%) |
| Efavirenz | 29 |
| Rilpivirine | 20 |
| Nevirapine | 1 |
| Etravirine | 3 |
| Integrase inhibitor | 68 (40%) |
| Raltegravir | 38 |
| Dolutegravir | 29 |
| Elvitegravir - cobicistat | 1 |
| NRTI | |
| Tenofovir (TDF) | 129 (75%) |
| Abacavir | 35 (20%) |
| Lamivudine or emtricitabine | 159 (92%) |
| Zidovudine | 7 (4%) |
| Didanosine | 1 (0.01%) |
| CCR5 Inhibitor | |
| Maraviroc | 1 (0.01%) |
| Tenofovir (TDF) + protease inhibitor (with ritonavir) | 53 (31%) |
Abbreviations: ALT, alanine aminotransferase; BMI, body mass index; BOC, boceprevir; CCR5, chemokine receptor 5; Fib, fibrosis; HCV, hepatitis C virus; HIV, human immunodeficiency virus; IDU, injection drug use; IFN, interferon-α; IQR, interquartile range; MSM, men whom have sex with men; NNRTI, nonnucleoside reverse-transcriptase inhibitor; NRTI, nucleoside reverse-transcriptase inhibitor; PEG-IFN, pegylated IFN-α; RBV, ribavirin; RNA, ribonucleic acid; Scr, serum creatinine; TDF, tenofovir disoproxil fumarate; TPV, telaprevir.